#1 Clinical Trials Search in Europe

Perflutren

This article summarizes several clinical trials investigating the use of perflutren (brand name Definity), an ultrasound contrast agent, for various medical imaging applications. Perflutren is a microbubble contrast agent that improves the clarity of ultrasound images. The trials examine its use in cardiac imaging, kidney lesion diagnosis, spinal cord injury assessment, and intracranial pressure monitoring.

Table of Contents

What is Perflutren?

Perflutren, also known by the brand name Definity[1], is a medical contrast agent used to enhance the quality of ultrasound images. It belongs to a class of substances called “microbubble contrast agents”[2]. These are tiny bubbles filled with gas and surrounded by a lipid (fat) shell. When injected into the bloodstream, these microbubbles can help doctors see blood flow and organ structures more clearly on ultrasound scans.

How Perflutren Works

When Perflutren is injected into your bloodstream, the microbubbles travel through your blood vessels. During an ultrasound examination, these bubbles reflect sound waves differently than surrounding tissues. This creates a clearer, more detailed image of your blood vessels and organs[3]. The microbubbles are very small (less than 8 micrometers in diameter) and can pass safely through even the tiniest blood vessels in your body[4].

Medical Uses of Perflutren

Perflutren is used in various medical imaging procedures to help diagnose and monitor different conditions:

  • Heart Imaging: It helps evaluate the function of heart chambers and blood flow within the heart. This is particularly useful for assessing conditions like heart failure or abnormalities in heart structure[5].
  • Kidney Imaging: Perflutren can help detect and characterize kidney tumors, especially in patients with chronic kidney disease who may not be able to use other types of contrast agents[2].
  • Liver Imaging: It aids in identifying and evaluating liver tumors, which is crucial for planning treatments like radiofrequency ablation (a procedure to destroy tumor cells)[6].
  • Brain Imaging: Researchers are exploring its use in measuring intracranial pressure (pressure inside the skull) non-invasively[4].
  • Spinal Cord Injury Assessment: It’s being studied to evaluate blood flow in the spinal cord after traumatic injuries[3].

How Perflutren is Administered

Perflutren is given as an intravenous (IV) injection or infusion. The exact method can vary depending on the specific procedure:

  • It may be given as a single injection[5].
  • In some cases, it’s mixed with saline solution and given as a slow infusion over several minutes[4].
  • The dose is usually small, often just a few milliliters[6].

The administration is typically done by a healthcare professional in a medical setting where ultrasound equipment is available.

Safety Profile

Perflutren has been used in clinical practice for many years and has a well-established safety profile. However, like all medical procedures, its use does carry some risks:

  • Most side effects, if they occur, are mild and short-lived[7].
  • In rare cases, more serious allergic reactions can occur.
  • It’s important to inform your doctor about any allergies or medical conditions you have before receiving Perflutren.

Large-scale studies have been conducted to monitor the safety of Perflutren in real-world clinical use[7].

Ongoing Research

Scientists continue to explore new ways to use Perflutren to improve medical imaging and patient care:

  • Researchers are studying its use in assessing blood flow in the spinal cord after traumatic injuries. This could help doctors better understand the extent of injury and guide treatment decisions[8].
  • There’s ongoing research into using Perflutren to measure pressure inside the skull non-invasively. This could be particularly helpful for conditions like idiopathic intracranial hypertension (increased pressure in the brain with no known cause)[4].
  • Studies are also looking at how Perflutren-enhanced ultrasound compares to other imaging techniques like MRI for measuring heart function[9].

These ongoing studies aim to expand the uses of Perflutren and improve its effectiveness in various medical conditions.

Application Key Findings/Objectives Potential Benefits
Cardiac Imaging Evaluating accuracy of left ventricular ejection fraction measurement Improved assessment of heart function, especially in patients with suboptimal echocardiograms
Kidney Lesion Diagnosis Assessing sensitivity and specificity in detecting kidney malignancies Better characterization of kidney lesions, particularly in patients with chronic kidney disease
Spinal Cord Injury Assessment Measuring blood flow changes in injured spinal cord tissue Potential to guide treatment and improve outcomes in acute spinal cord injuries
Intracranial Pressure Monitoring Using SHAPE technique to estimate pressure in ophthalmic artery Non-invasive method for monitoring intracranial pressure in various conditions
Safety Surveillance Monitoring for adverse events in clinical practice Ensuring ongoing safety of perflutren use in diverse patient populations

FAQ

  • What is perflutren (Definity) used for? Perflutren, sold under the brand name Definity, is an ultrasound contrast agent used to improve the clarity and accuracy of ultrasound imaging. It contains microscopic gas-filled bubbles that enhance the visibility of blood flow and tissue boundaries during ultrasound scans.
  • What medical conditions are being studied using perflutren-enhanced ultrasound? The clinical trials are investigating the use of perflutren-enhanced ultrasound for several conditions, including cardiac function assessment, diagnosis of kidney lesions, evaluation of spinal cord injuries, and monitoring of intracranial pressure.
  • How is perflutren administered during the ultrasound procedure? Perflutren is typically administered intravenously, either as a bolus injection or as a continuous infusion. The dosage and administration method may vary depending on the specific imaging application and study protocol.
  • Are there any safety concerns with using perflutren? While perflutren is generally considered safe, some trials are specifically monitoring for adverse events. One study is evaluating the occurrence of serious cardiopulmonary events within 30 minutes of administration. As with any medical procedure, patients should discuss potential risks with their healthcare provider.
  • How might perflutren-enhanced ultrasound benefit patients? Perflutren-enhanced ultrasound may provide more accurate imaging compared to standard ultrasound, potentially improving diagnosis and treatment planning for various conditions. It may be especially beneficial for patients who cannot undergo other types of contrast-enhanced imaging due to kidney problems or other contraindications.

Ongoing Clinical Trials on Perflutren

  • Study Comparing Apixaban and Warfarin for Patients with Heart Clots After a Heart Attack

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Sweden

  • Study on Glioblastoma Recurrence: Comparing SonoCloud-9 with Carboplatin to Standard Treatments Lomustine or Temozolomide for Patients Undergoing Tumor Removal Surgery

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Denmark France Germany Italy +3

  • Safety and imaging quality study of perflutren contrast agent (HarMono-T) during kidney ultrasound in healthy volunteers

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Germany

  • Study on Glioblastoma Treatment with Temozolomide, Lomustine, and Perflutren for Newly Diagnosed Patients

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France

  • Study on the Effects of Ianalumab in Patients with Sjögren’s Syndrome

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Perflutren: An ultrasound contrast agent consisting of gas-filled microspheres that enhance the visibility of blood flow and tissue boundaries during ultrasound imaging. Also known by the brand name Definity.
  • Contrast-enhanced ultrasound (CEUS): An ultrasound technique that uses contrast agents like perflutren to improve image quality and provide more detailed information about blood flow and tissue characteristics.
  • Ejection fraction (EF): A measurement of how much blood the left ventricle pumps out with each contraction, used to assess heart function.
  • Chronic kidney disease (CKD): A condition characterized by gradual loss of kidney function over time, which can increase the risk of kidney lesions and complicate imaging procedures.
  • Bosniak criteria: A classification system used to categorize kidney cysts based on their appearance on imaging, helping to determine the risk of malignancy.
  • Intracranial pressure (ICP): The pressure inside the skull and brain tissue, which can be elevated in certain medical conditions and may require monitoring.
  • Subharmonic Aided Pressure Estimation (SHAPE): A novel ultrasound technique that uses the subharmonic signals from contrast agents to estimate pressure within blood vessels or organs.
  • Traumatic spinal cord injury (tSCI): Damage to the spinal cord caused by trauma, which can lead to loss of function and requires careful assessment and management.
  • Secondary injury: Additional damage that occurs after the initial trauma in spinal cord injuries, often due to reduced blood flow and swelling.
  • Cardiac magnetic resonance imaging (CMR): A specialized MRI technique used to image the heart, often considered a gold standard for assessing cardiac function.

References

  1. https://clinicaltrials.gov/study/NCT01544036
  2. https://clinicaltrials.gov/study/NCT03196076
  3. https://clinicaltrials.gov/study/NCT06654804
  4. https://clinicaltrials.gov/study/NCT06571786
  5. https://clinicaltrials.gov/study/NCT03719612
  6. https://clinicaltrials.gov/study/NCT00584402
  7. https://clinicaltrials.gov/study/NCT00625365
  8. https://clinicaltrials.gov/study/NCT04056988
  9. https://clinicaltrials.gov/study/NCT03571672